์ฃผ์š” ์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ

SUTRO BIOPHARMA, INC. (STRO) ์ฃผ์‹ ์˜ˆ์ธก 2025 - AI ๊ฐ€๊ฒฉ ์˜ˆ์ธก ๋ฐ ๋ถ„์„


SUTRO BIOPHARMA, INC. (STRO) AI ์ฃผ๊ฐ€ ์˜ˆ์ธก ๋ฐ ํˆฌ์ž ๋ถ„์„

SUTRO BIOPHARMA, INC. ์ฃผ๊ฐ€ ์ฐจํŠธ ๋ฐ ๊ธฐ์ˆ ์  ๋ถ„์„

SUTRO BIOPHARMA, INC. ๋Œ€ํ™”ํ˜• ๊ฐ€๊ฒฉ ์ฐจํŠธ ๋ฐ ๊ธฐ์ˆ  ๋ถ„์„ ๋กœ๋“œ ์ค‘...

SUTRO BIOPHARMA, INC. (STRO) - ์ข…ํ•ฉ์ ์ธ ์ฃผ์‹ ๋ถ„์„ ๋ฐ ํˆฌ์ž ๋ฆฌ์„œ์น˜

ํšŒ์‚ฌ ๊ฐœ์š” ๋ฐ ๋น„์ฆˆ๋‹ˆ์Šค ํ”„๋กœํ•„

SUTRO BIOPHARMA, INC. (์ฃผ์‹ ๊ธฐํ˜ธ: STRO) ๋Š” Life Sciences ๋ถ€๋ฌธ์˜ ์„ ๋„ ๊ธฐ์—…์ž…๋‹ˆ๋‹ค. ํŠนํžˆ Biological Products, (No Diagnostic Substances) ์‚ฐ์—… ๋‚ด์—์„œ ์šด์˜๋ฉ๋‹ˆ๋‹ค.. ์ „ ์„ธ๊ณ„ ์•ฝ 260๋ช…์˜ ์ „๋ฌธ๊ฐ€๋ฅผ ๊ณ ์šฉํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. . ํšŒ์‚ฌ ๋กœ ์ž๋ฆฌ๋งค๊น€ํ–ˆ์Šต๋‹ˆ๋‹ค. ์ƒ๋‹นํ•œ ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์„ ๊ฐ€์ง„ ์ƒˆ๋กœ์šด ํˆฌ์ž ๊ธฐํšŒ.

์žฌ๋ฌด ์„ฑ๊ณผ ๋ฐ ์ฃผ์š” ์ง€ํ‘œ ๋ถ„์„

์—ฐ๊ฐ„ ์ˆ˜์ต: $104 ๋ฐฑ๋งŒ -855.1% ์ˆœ์ด์ต๋ฅ  ์ƒ์„ฑ .

์‹œ๊ฐ€์ด์•ก: $73 ๋ฐฑ๋งŒ - ๋กœ ๋ถ„๋ฅ˜ ๋†’์€ ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์„ ์ œ๊ณตํ•˜๋Š” ์†Œํ˜•์ฃผ ํˆฌ์ž.

์ž๊ธฐ์ž๋ณธ ์ˆ˜์ต๋ฅ (ROE): -43.3% - ํ‰๊ท  ์ดํ•˜ ์ฃผ์ฃผ ํ™˜์› ํšจ์œจ์„ฑ์„ ๋‚˜ํƒ€๋‚ด๋Š” ์šด์˜ ๊ฐœ์„ ์ด ํ•„์š”ํ•œ ์˜์—ญ.

๊ณ ๊ธ‰ AI ์ฃผ์‹ ์˜ˆ์ธก ๋ฐ ๋ชฉํ‘œ๊ฐ€ ๋ถ„์„

๐Ÿš€ ํ”„๋ฆฌ๋ฏธ์—„ AI ์˜ˆ์ธก ๊ธฐ๋Šฅ ์ž ๊ธˆ ํ•ด์ œ ๋ฅผ ํด๋ฆญํ•˜๋ฉด 7์ผ, 30์ผ, 90์ผ ๊ฐ€๊ฒฉ ๋ชฉํ‘œ์™€ ์‹ ๋ขฐ ๊ตฌ๊ฐ„ ๋ฐ ์œ„ํ—˜ ํ‰๊ฐ€๋ฅผ ํฌํ•จํ•œ SUTRO BIOPHARMA, INC. ์ฃผ์‹์— ๋Œ€ํ•œ ๊ณ ๊ธ‰ ๋จธ์‹  ๋Ÿฌ๋‹ ์˜ˆ์ธก์— ์•ก์„ธ์Šคํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์‹œ์žฅ ์ง€์œ„ ๋ฐ ๊ฒฝ์Ÿ ์šฐ์œ„ ๋ถ„์„

SUTRO BIOPHARMA, INC.๋Š” ๋งค์šฐ ์—ญ๋™์ ์ธ ํ™˜๊ฒฝ์—์„œ ์ „๋žต์ ์œผ๋กœ ๊ฒฝ์Ÿํ•ฉ๋‹ˆ๋‹ค. Biological Products, (No Diagnostic Substances) ๋งˆ์ผ“ํ”Œ๋ ˆ์ด์Šค, ์ƒ๋‹นํ•œ ์„ฑ์žฅ ์ž ์žฌ๋ ฅ๊ณผ ์‹œ์žฅ ํŒŒ๊ดด์  ์—ญ๋Ÿ‰์„ ๊ฐ–์ถ˜ ์‹ ํฅ ์†Œํ˜•์ฃผ ํˆฌ์ž๋ฅผ ๋Œ€ํ‘œํ•ฉ๋‹ˆ๋‹ค. . ์ด ํšŒ์‚ฌ๋Š” ๊ฑด์ „ํ•œ 43.7% ์ด ๋งˆ์ง„์„ ์œ ์ง€ํ•˜์—ฌ ๊ฐ•๋ ฅํ•œ ๊ฐ€๊ฒฉ ์ฑ…์ •๋ ฅ๊ณผ ์šด์˜ ํšจ์œจ์„ฑ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.

SUTRO BIOPHARMA, INC. (STRO) ๊ธฐ๋ณธ ๋ถ„์„ ๋ฐ ๋‚ด๋ถ€์ž ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ (๋ถ„๊ธฐ๋ณ„ ์žฌ๋ฌด ๋ณด๊ณ ์„œ)

๋‹ค์Œ์— ๋Œ€ํ•œ ์ข…ํ•ฉ์ ์ธ ๋ถ„๊ธฐ๋ณ„ ์žฌ๋ฌด ๋ฐ์ดํ„ฐ, ์ˆ˜์ต ๋™ํ–ฅ, ๋‚ด๋ถ€์ž ๊ฑฐ๋ž˜ ๋ฐ ๊ธฐ๊ด€ ๋ณด์œ  ํ˜„ํ™ฉ์„ ํ™•์ธํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. SUTRO BIOPHARMA, INC. ์ฃผ์‹ ๋ถ„์„.

์ข…ํ•ฉ ํŽ€๋”๋ฉ˜ํ„ธ ๋ถ„์„ ๋ฐ ๋‚ด๋ถ€์ž ๊ฑฐ๋ž˜ ๋ฐ์ดํ„ฐ SUTRO BIOPHARMA, INC. ๋กœ๋“œ ์ค‘...

SUTRO BIOPHARMA, INC.์˜ ์žฌ๋ฌด ์ƒํƒœ, ๊ฐ€์น˜ ํ‰๊ฐ€ ์ง€ํ‘œ, ์šด์˜ ํšจ์œจ์„ฑ์„ ์ž์„ธํžˆ ์‚ดํŽด๋ณด๊ณ  ์ •๋ณด์— ์ž…๊ฐํ•œ ํˆฌ์ž ๊ฒฐ์ •์„ ๋‚ด๋ฆฌ์„ธ์š”.

๊ฐ€์น˜ ํ‰๊ฐ€ ์ง€ํ‘œ ์ดํ•ด

์ด๋Ÿฌํ•œ ๋ฉ”ํŠธ๋ฆญ์˜ ์˜๋ฏธ: ๊ฐ€์น˜ ํ‰๊ฐ€ ์ง€ํ‘œ๋Š” SUTRO BIOPHARMA, INC. ์ฃผ์‹์ด ์ˆ˜์ต, ์ž์‚ฐ ๋ฐ ์‹œ์žฅ ํฌ์ง€์…˜์— ๋น„ํ•ด ๊ณต์ •ํ•œ ๊ฐ€๊ฒฉ์ธ์ง€ ํŒ๋‹จํ•˜๋Š” ๋ฐ ๋„์›€์ด ๋ฉ๋‹ˆ๋‹ค.

์ฝ๋Š” ๋ฐฉ๋ฒ•: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

SUTRO BIOPHARMA, INC.์˜ ๊ฒฝ์šฐ: P/E ๋น„์œจ์ด -1.04์ธ ๊ฒฝ์šฐ, ์‹œ์žฅ ์ฃผ์‹์ด ์ž ์žฌ์ ์œผ๋กœ ์ €ํ‰๊ฐ€๋˜์—ˆ๋‹ค๊ณ  ํŒ๋‹จํ•˜๋Š” ๊ฒฝ์šฐ.

P/E Ratio -1.04x
P/B Ratio -2.52x
Market Cap $73M
Dividend Yield 6.48%
EPS $-2.51
์žฅ๋ถ€๊ฐ€/์ฃผ์‹ $-0.31
์ˆ˜์ต/๊ณต์œ  $1.23
FCF/๊ณต์œ  $-2.44
์ˆ˜์ต์„ฑ ์ง€ํ‘œ ์ดํ•ด

์ด๋Ÿฌํ•œ ๋ฉ”ํŠธ๋ฆญ์˜ ์˜๋ฏธ: ์ด ๋น„์œจ์€ SUTRO BIOPHARMA, INC.๊ฐ€ ์–ผ๋งˆ๋‚˜ ํšจ์œจ์ ์œผ๋กœ ์ˆ˜์ต์„ ์ˆ˜์ต์œผ๋กœ ์ „ํ™˜ํ•˜๊ณ  ์ฃผ์ฃผ์—๊ฒŒ ์ˆ˜์ต์„ ์ฐฝ์ถœํ•˜๋Š”์ง€๋ฅผ ์ธก์ •ํ•ฉ๋‹ˆ๋‹ค.

์ฝ๋Š” ๋ฐฉ๋ฒ•: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

SUTRO BIOPHARMA, INC.์˜ ๊ฒฝ์šฐ: ROE -43.3% ์—์„œ ๊ฐœ์„ ์˜ ์—ฌ์ง€๊ฐ€ ์žˆ์Œ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ์ฃผ์ฃผ ๊ฐ€์น˜ ์ฐฝ์ถœ.

ROE -43.3%
ROA -34.5%
ROIC -35.9%
Gross Margin 43.7%
Operating Margin -1659.6%
Net Margin -855.1%
EBT Margin -215.2%
Tax Rate 11.7%
์žฌ๋ฌด ์ƒํƒœ ์ง€ํ‘œ ์ดํ•ด

์ด๋Ÿฌํ•œ ๋ฉ”ํŠธ๋ฆญ์˜ ์˜๋ฏธ: ์ด ๋น„์œจ์€ SUTRO BIOPHARMA, INC.๊ฐ€ ๋‹จ๊ธฐ ์˜๋ฌด๋ฅผ ์ดํ–‰ํ•˜๊ณ  ๋ถ€์ฑ„ ์ˆ˜์ค€์„ ํšจ๊ณผ์ ์œผ๋กœ ๊ด€๋ฆฌํ•  ์ˆ˜ ์žˆ๋Š” ๋Šฅ๋ ฅ์„ ํ‰๊ฐ€ํ•ฉ๋‹ˆ๋‹ค.

์ฝ๋Š” ๋ฐฉ๋ฒ•: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

SUTRO BIOPHARMA, INC.์˜ ๊ฒฝ์šฐ: ํ˜„์žฌ ๋น„์œจ์€ 5.90์ž…๋‹ˆ๋‹ค. ๋Š” ๊ฐ•ํ•œ ์œ ๋™์„ฑ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค..

Current Ratio 5.90x
Quick Ratio 5.70x
D/E Ratio 0.20x
Financial Leverage 1.37x
Interest Coverage -37.9x
Working Capital $349M
ํ˜„๊ธˆ ํ๋ฆ„ ์ง€ํ‘œ ์ดํ•ด

์ด๋Ÿฌํ•œ ๋ฉ”ํŠธ๋ฆญ์˜ ์˜๋ฏธ: ํ˜„๊ธˆ ํ๋ฆ„ ๋ฉ”ํŠธ๋ฆญ์€ SUTRO BIOPHARMA, INC.์˜ ์šด์˜ ํ˜„๊ธˆ ์ฐฝ์ถœ ๋Šฅ๋ ฅ๊ณผ ์„ฑ์žฅ ์ด๋‹ˆ์…”ํ‹ฐ๋ธŒ์— ๋Œ€ํ•œ ์ž๊ธˆ ์กฐ๋‹ฌ ๋Šฅ๋ ฅ์„ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค.

์ฝ๋Š” ๋ฐฉ๋ฒ•: ๊ธ์ •์ ์ธ ์˜์—… ํ˜„๊ธˆ ํ๋ฆ„์€ ๋งค์šฐ ์ค‘์š”ํ•ฉ๋‹ˆ๋‹ค. ์ž‰์—ฌ ํ˜„๊ธˆ ํ๋ฆ„์€ ๋ฐฐ๋‹น, ํ™˜๋งค ๋˜๋Š” ํˆฌ์ž์— ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋Š” ์ž๊ธˆ์„ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค.

SUTRO BIOPHARMA, INC.์˜ ๊ฒฝ์šฐ: ์ž‰์—ฌํ˜„๊ธˆํ๋ฆ„ $-101M ์ฃผ์˜๊ฐ€ ํ•„์š”ํ•œ ํ˜„๊ธˆ ๋ฌธ์ œ๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค..

Operating Cash Flow $-87M
Free Cash Flow $-101M
Capital Spending $-15M
FCF/Sales -190.2%
CapEx/Sales 27.3%
์šด์˜ ํšจ์œจ์„ฑ ์ง€ํ‘œ์— ๋Œ€ํ•œ ์ดํ•ด

์ด๋Ÿฌํ•œ ๋ฉ”ํŠธ๋ฆญ์˜ ์˜๋ฏธ: ์ด ๋น„์œจ์€ SUTRO BIOPHARMA, INC.๊ฐ€ ์ž์‚ฐ์„ ์–ผ๋งˆ๋‚˜ ํšจ๊ณผ์ ์œผ๋กœ ์‚ฌ์šฉํ•˜๊ณ  ์šด์ „ ์ž๋ณธ์„ ๊ด€๋ฆฌํ•˜๋Š”์ง€๋ฅผ ์ธก์ •ํ•ฉ๋‹ˆ๋‹ค.

์ฝ๋Š” ๋ฐฉ๋ฒ•: ํšŒ์ „์œจ์ด ๋†’์„์ˆ˜๋ก ์ž์‚ฐ ํ™œ์šฉ์ด ํšจ์œจ์ ์ด๋ผ๋Š” ๋œป์ž…๋‹ˆ๋‹ค. ํšŒ์ˆ˜ ๊ธฐ๊ฐ„์ด ์งง์„์ˆ˜๋ก ํšจ๊ณผ์ ์ธ ์‹ ์šฉ ๊ด€๋ฆฌ๊ฐ€ ์ด๋ฃจ์–ด์ง€๊ณ  ์žˆ์Œ์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค.

SUTRO BIOPHARMA, INC.์˜ ๊ฒฝ์šฐ: ์ž์‚ฐ ํšŒ์ „์œจ 0.16x ์—์„œ ๊ฐœ์„ ์˜ ์—ฌ์ง€๊ฐ€ ์žˆ์Œ์„ ์‹œ์‚ฌํ•ฉ๋‹ˆ๋‹ค. ์ž์‚ฐ ํ™œ์šฉ๋„.

Asset Turnover 0.16x
Receivables Turnover 5.6x
Fixed Assets Turnover 1.6x
ํŒ๋งค ๋ฏธ๊ฒฐ ์ผ์ˆ˜ 65 ์ผ์ˆ˜
์žฌ๋ฌด ์ œํ‘œ ๋ฐ์ดํ„ฐ ์ดํ•ด

์ด๋Ÿฌํ•œ ๋ฉ”ํŠธ๋ฆญ์˜ ์˜๋ฏธ: ์ ˆ๋Œ€ ์žฌ๋ฌด ์„ฑ๊ณผ๋ฅผ ๋ณด์—ฌ์ฃผ๋Š” SUTRO BIOPHARMA, INC.์˜ ์†์ต ๊ณ„์‚ฐ์„œ ๋ฐ ๋Œ€์ฐจ ๋Œ€์กฐํ‘œ์˜ ์ฃผ์š” ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

์ฝ๋Š” ๋ฐฉ๋ฒ•: ์ˆ˜์ต์€ ์‚ฌ์—… ๊ทœ๋ชจ๋ฅผ ๋‚˜ํƒ€๋‚ด๊ณ  ๋งˆ์ง„์€ ์ˆ˜์ต์„ฑ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ๋Œ€์ฐจ ๋Œ€์กฐํ‘œ ํ•ญ๋ชฉ์€ ์žฌ๋ฌด ๊ตฌ์กฐ๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.

SUTRO BIOPHARMA, INC.์˜ ๊ฒฝ์šฐ: ์—ฐ๊ฐ„ ์ˆ˜์ต์ด $104M, SUTRO BIOPHARMA, INC.์ธ ๊ฒฝ์šฐ ๊ฒฌ๊ณ ํ•œ ๋น„์ฆˆ๋‹ˆ์Šค ๊ทœ๋ชจ๋ฅผ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค..

์†์ต ๊ณ„์‚ฐ์„œ ($ ์ˆ˜๋ฐฑ๋งŒ)
์ด ์ˆ˜์ต $104M
R&D ๋น„์šฉ $235M
ํŒ๊ด€๋น„ $113M
๋Œ€์ฐจ ๋Œ€์กฐํ‘œ ์ฃผ์š” ๋‚ด์šฉ ($ ์ˆ˜๋ฐฑ๋งŒ)
Total Current Assets $75M
Cash & Short-term Investments $69M
Total Liabilities $27M
Short-term Debt $4M
Accounts Receivable $4M
๋ฐฐ๋‹น๊ธˆ ๋ฐ ์ฃผ์ฃผ ์ •๋ณด
Dividends Per Share $1.37
Payout Ratio 43.6%
Shares Outstanding 85M
์„ฑ์žฅ ์ง€ํ‘œ(์ „๋…„ ๋Œ€๋น„)
EPS Growth -74.7%

์ตœ์‹  SUTRO BIOPHARMA, INC. ์ฃผ์‹ ๋‰ด์Šค ๋ฐ ์‹œ์žฅ ๋ถ„์„

SUTRO BIOPHARMA, INC. (STRO) ์ฃผ๊ฐ€ ๋ฐ ํˆฌ์ž ์ „๋ง์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ์†๋ณด, ์• ๋„๋ฆฌ์ŠคํŠธ ๋ณด๊ณ ์„œ ๋ฐ ์‹œ์žฅ ์—…๋ฐ์ดํŠธ.

๐Ÿ“ฐ ํ˜„์žฌ SUTRO BIOPHARMA, INC.์— ๋Œ€ํ•œ ๋‰ด์Šค ํ”ผ๋“œ๋ฅผ ์—…๋ฐ์ดํŠธํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์ตœ์‹  ์‹œ์žฅ ๋ถ„์„ ๋ฐ ํšŒ์‚ฌ ์—…๋ฐ์ดํŠธ๋ฅผ ๊ณง ๋‹ค์‹œ ํ™•์ธํ•ด ์ฃผ์„ธ์š”.

SUTRO BIOPHARMA, INC. ๊ฒฝ์Ÿ์‚ฌ ๋ฐ ๋™์ข…์—…๊ณ„ ๋ถ„์„ - Life Sciences ์„นํ„ฐ

AI ๊ธฐ๋ฐ˜ ์˜ˆ์ธก๊ณผ ์ฃผ์š” ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ํ†ตํ•ด Life Sciences ๋ถ€๋ฌธ์˜ ์—…๊ณ„ ๋™๋ฃŒ ๋ฐ ๊ฒฝ์Ÿ์‚ฌ์™€ SUTRO BIOPHARMA, INC.์„ ๋น„๊ต ๋ถ„์„ํ•ฉ๋‹ˆ๋‹ค.

ํšŒ์‚ฌ ํ‹ฐ์ปค ๊ธฐํ˜ธ 90์ผ AI ์˜ˆ๋ณด ์‹œ๊ฐ€์ด์•ก(USD M) P/E ๋น„์œจ P/B ๋น„์œจ
ABOS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $82M -1.9x 0.7x
ABP ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x 0.0x
ABPWW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x 0.0x
ACLX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $3725M -74.1x 8.9x
ACOG ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $133M x 4.2x
ADAP ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $94M -13.2x -11.8x
ADMA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4227M 20.2x 10.6x
ADPT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1969M -4.6x 11.0x
ADVM ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $58M -1.8x 2.2x
AGEN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $125M -0.5x -0.5x
AIM ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2M -0.5x -183.3x
AIMI ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2M x x
ALEC ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $238M -1.2x 3.3x
ALGS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $99M -19.2x 1.0x
ALLO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $249M -1.4x 0.7x
ALVR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $49M -0.5x 0.4x
AMGN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $155224M 23.5x 20.9x
APGE ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2248M -20.5x 4.3x
APTO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $6M 0.0x -1.3x
APTOF ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $3M x x
ARMP ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $90M -1.0x -1.6x
ARTV ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $77M x 0.5x
ATHA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $15M -0.2x 0.5x
ATRA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $139M 24.1x -1.1x
ATYR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $515M -3.6x 6.9x
AURA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $389M -4.9x 2.2x
AUTL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $399M x 1.2x
AVXL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $823M -17.3x 9.1x
BCAB ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $125M -1.1x 1.0x
BCDA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $12M -0.6x -7.8x
BCLI ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $8M -4.9x -0.9x
BCRX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1802M -12.1x -4.0x
BDTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $158M 11.0x 1.2x
BEAM ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1831M -12.6x 1.8x
BIIB ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $18125M 12.8x 1.5x
BKHA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x 0.0x
BKHAU ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x 0.0x
BLUE ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $49M -0.2x -0.8x
CABA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $133M -1.6x 0.7x
CADL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $338M -4.6x 4.5x
CCCC ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $185M -2.6x 1.1x
CDTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $728M -1.0x 5.1x
CELZ ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $8M -3.4x 1.2x
CERO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2M x -196.2x
CEROW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2M x -0.5x
CGEM ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $449M -4.1x 0.8x
CGEN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $132M x 2.6x
CGON ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2103M x 3.1x
CGTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $158M -0.5x 22.5x
CHRO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $8M x -2.0x
CHRS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $135M 0.8x 1.1x
CLDI ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $6M -0.9x 3.2x
CMPX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $483M -4.8x 5.2x
COEPW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $M x x
CRBU ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $174M -1.5x 1.1x
CRDF ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $140M -4.0x 2.4x
CRGX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $215M x 0.9x
CRIS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $18M -0.3x -2.9x
CRSP ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4654M -12.1x 2.7x
CSBR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $111M -17.8x 20.4x
CVM ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $56M -0.9x 7.9x
CYTH ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $26M -0.6x -1.9x
CYTHW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $7M x -0.5x
DBVT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1479M -3.3x 514.8x
DNA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $568M -13.9x 0.3x
DNLI ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2111M -8.7x 1.9x
DTIL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $57M -2.2x 1.7x
DYAI ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $28M -7.3x 11.4x
EDIT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $231M -0.8x 3.7x
ELEV ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $22M -1.0x 0.5x
ELUT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $102M -1.4x -0.1x
ENGN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $236M 3.7x 1.0x
ENGNW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $37M x 0.1x
ENTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $88M 8.5x 5.1x
ENZ ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $25M -3.0x 0.5x
ENZB ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $37M x 0.8x
ESLA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $39M -3.1x -16.9x
ESLAW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4M x 5.3x
EXEL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $10644M 17.7x 5.2x
EXOZ ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $81M x 11.2x
FATE ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $123M -1.3x 0.5x
FDMT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $344M -3.0x 0.8x
FENC ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $246M 1758.3x -39.7x
FNCH ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $21M -0.1x 1.5x
FTII ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $-26M x -0.7x
FTIIU ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $-26M x -0.8x
FTIIW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x 0.0x
GILD ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $141676M 22.5x 7.2x
GLUE ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $398M 16.5x 1.5x
GNTA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $69M x 5.5x
GPLB ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $M x x
HALO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $9201M 16.5x 27.7x
HLVX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $105M -0.6x 0.7x
HUMA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $242M -3.3x 59.8x
HUMAW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $163M x -2.6x
IBRX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2427M -3.6x -4.1x
IKNA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $61M -1.3x 0.5x
IKT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $162M -1.0x 2.0x
IMCR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1731M x 4.5x
IMVT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2669M -14.5x 4.4x
INAB ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $21M -0.4x 2.4x
INBX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $436M -6.8x 6.4x
INKT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $57M -1.5x -1.4x
INMB ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $54M -2.5x 1.9x
INTS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $7M -2.2x 3.4x
IOVA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $762M -4.5x 1.1x
IPSC ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $42M -0.7x 0.2x
ITOS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $393M -2.8x 0.7x
IVVD ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $117M -0.4x 2.7x
IZTC ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $99M x -27.5x
JSPR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $45M -3.2x 1.9x
JSPRW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $3M x 0.0x
KLRS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $76M x 1.4x
KLTO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $37M x 3.4x
KLTOW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1M x 0.4x
KOD ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $478M -2.5x 6.8x
KRBPQ ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x x
KRYS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4443M 30.3x 4.3x
KYMR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $3373M -17.8x 3.5x
KYTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $160M x 0.9x
LADX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $M x x
LCTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $260M -4.7x 5.4x
LENZ ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1116M -6.7x 5.4x
LIMN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x x
LXEO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $259M -0.4x 1.9x
MAZE ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $635M x 2.4x
MGTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $693M -3.4x 20.9x
MGX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $65M x 0.3x
MRNA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $9410M -3.2x 1.0x
NBIX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $14447M 41.5x 5.4x
NKGN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4M -0.1x -0.2x
NKGNW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1M x 0.0x
NMRA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $280M -3.9x 1.5x
NVAX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1339M 3.2x 35.6x
OCGN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $298M -4.3x 18.7x
OMGA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $9M -0.7x 0.8x
OMGAQ ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x 0.0x
ONVO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $35M -0.4x 95.9x
OTLK ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $73M -0.2x -2.3x
PALI ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4M -0.2x 0.7x
PASG ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $23M -0.6x 0.6x
PCVX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4288M -20.4x 1.4x
PHGE ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $15M 1.5x 0.8x
PLUR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $-4M -1.4x -9.1x
PLX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $120M 19.2x 2.4x
PMCB ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $7M -2.6x 0.2x
PRME ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $436M -1.5x 7.2x
PROK ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $-65M x 0.0x
PSTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $926M -9.6x 10.6x
PTHS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $M x x
QGEN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $10544M x 3.0x
QNCX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $86M -1.7x 7.3x
REPL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $932M -3.8x 2.2x
RGEN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $6531M 8219.1x 3.3x
RGNX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $459M -1.8x 2.2x
RLAY ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $628M -2.0x 0.9x
RVMD ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $7134M -11.1x 3.4x
RVMDW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $16M x 0.0x
RXRX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2000M -4.7x 2.2x
SABS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $24M -2.3x 1.1x
SABSW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x 0.0x
SANA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $728M -2.1x 5.9x
SCLX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $62M -0.4x -0.3x
SCLXW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $25M x -0.1x
SCNI ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $5125M -287.8x -2577.2x
SGMO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $124M -1.6x 6.3x
SLDB ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $495M -0.9x 1.7x
SLXN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4M x 35.4x
SLXNW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $866M x -189.1x
SNTI ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $51M -1.1x 1.3x
SRRK ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $4069M -18.5x 13.0x
SRZN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $104M -0.5x 2.2x
SRZNW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $0M x 0.0x
STRO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $73M -1.0x -2.5x
SWTX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $3539M -9.9x 8.5x
TARA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $129M -2.1x 0.9x
TARS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $2454M -12.4x 7.4x
TCBP ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $37M x 34.5x
TCBPW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1M x 1.0x
TCBPY ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $21M x 19.6x
TCRX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $233M -4.6x 1.3x
TECH ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $8155M 75.2x 4.0x
TECX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $478M -8.9x 1.7x
TIL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $182M -1.1x 1.3x
TNYA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $154M -2.5x 1.5x
TRML ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $602M -3.5x 2.3x
TSBX ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $8M -0.1x 0.6x
TSHA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $828M -3.0x 3.3x
TTNP ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $8M -0.5x 4.5x
TVGN ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $176M x -29.3x
TVGNW ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $11M x -1.9x
TWST ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1571M -12.6x 3.3x
VACH ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $-1436M x 0.0x
VACHU ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $-1585M x 0.0x
VCEL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $1712M 240.9x 5.6x
VIGL ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $384M -1.1x 9.3x
VIR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $686M -2.0x 0.7x
VIVS ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $3M x 0.3x
VOR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $248M -0.6x 3.9x
VXRT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $89M -0.9x 2.7x
VYGR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $197M 570.6x 0.8x
WINT ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $18M -0.4x 4.2x
XFOR ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $8M 6.4x 0.4x
ZIVO ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $65M -31.3x -2.0x
ZURA ์˜ˆ์ธก ์ž ๊ธˆ ํ•ด์ œ $131M 5.0x 0.9x

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ - SUTRO BIOPHARMA, INC. ์žฌ๊ณ  ์˜ˆ์ธก

SUTRO BIOPHARMA, INC. ์ฃผ์‹ ์˜ˆ์ธก์€ ์–ผ๋งˆ๋‚˜ ์ •ํ™•ํ•ฉ๋‹ˆ๊นŒ?

Our AI model demonstrates 59% historical accuracy for STRO predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

๋ณ€์ˆ˜_0__ ์ฃผ๊ฐ€ ์˜ˆ์ธก์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ์š”์ธ์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๋ถ„์„์—๋Š” SUTRO BIOPHARMA, INC.์˜ ์žฌ๋ฌด ์ง€ํ‘œ, Life Sciences ์„นํ„ฐ ๋™ํ–ฅ, ์‹œ์žฅ ์‹ฌ๋ฆฌ, ๊ธฐ์ˆ  ์ง€ํ‘œ, ์ˆ˜์ต ๋ฐ์ดํ„ฐ ๋ฐ ์ฃผ์‹ ์„ฑ๊ณผ์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ๊ฑฐ์‹œ ๊ฒฝ์ œ ์š”์ธ์ด ๊ณ ๋ ค๋ฉ๋‹ˆ๋‹ค.

2025๋…„์— SUTRO BIOPHARMA, INC.์ด ์ข‹์€ ํˆฌ์ž์ธ๊ฐ€์š”?

AI ๋ถ„์„์— ๋”ฐ๋ฅด๋ฉด SUTRO BIOPHARMA, INC.๋Š” ๋‹ค์Œ์„ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค. ๋‹ค์–‘ํ•œ ์‹œ์žฅ ์‹œ๋‚˜๋ฆฌ์˜ค์— ๋Œ€ํ•œ ์ž ์žฌ๋ ฅ. ํˆฌ์ž ๊ฒฐ์ •์„ ๋‚ด๋ฆฌ๊ธฐ ์ „์— ์ž์‹ ์˜ ์œ„ํ—˜ ๊ฐ๋‚ด ๋Šฅ๋ ฅ, ํˆฌ์ž ์ผ์ •, ํฌํŠธํด๋ฆฌ์˜ค ๋‹ค๊ฐํ™”๋ฅผ ๊ณ ๋ คํ•˜์„ธ์š”.

SUTRO BIOPHARMA, INC. ์˜ˆ์ธก์€ ์–ผ๋งˆ๋‚˜ ์ž์ฃผ ์—…๋ฐ์ดํŠธ๋˜๋‚˜์š”?

SUTRO BIOPHARMA, INC. ์ฃผ์‹ ์˜ˆ์ธก์€ ์‹ค์‹œ๊ฐ„ ์‹œ์žฅ ๋ฐ์ดํ„ฐ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ๋งค์ผ ์—…๋ฐ์ดํŠธ๋˜๋ฏ€๋กœ ์ตœ์‹  AI ๊ธฐ๋ฐ˜ ์˜ˆ์ธก๊ณผ ํˆฌ์ž ์ธ์‚ฌ์ดํŠธ๋ฅผ ๋ฐ›์•„๋ณผ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

๊ณ ๊ธ‰ SUTRO BIOPHARMA, INC. ๋ถ„์„์„ ์›ํ•˜์‹œ๋‚˜์š”?

์ž์„ธํ•œ ๊ฐ€๊ฒฉ ๋ชฉํ‘œ, ์œ„ํ—˜ ํ‰๊ฐ€, ํฌํŠธํด๋ฆฌ์˜ค ์ตœ์ ํ™”, SUTRO BIOPHARMA, INC. ์ฃผ์‹์— ๋Œ€ํ•œ ์‹ค์‹œ๊ฐ„ ์•Œ๋ฆผ ๋“ฑ ํ”„๋ฆฌ๋ฏธ์—„ ๊ธฐ๋Šฅ์„ ์ž ๊ธˆ ํ•ด์ œํ•˜์„ธ์š”.

๋‚ด ํฌํŠธํด๋ฆฌ์˜ค

ํˆฌ์ž ๋Œ€์‹œ๋ณด๋“œ

ํฌํŠธํด๋ฆฌ์˜ค ๋กœ๋“œ ์ค‘...